Is BioNTech SE (BNTX) a Buy, Sell, or Hold?
BioNTech SE
NASDAQ:BNTX
$118.39 USD
-$2.33 (-1.93%)
- Volume
- 516.09K
- Average Volume
- 1.14M
- Market Capitalization
- $28.38B
- P/E Ratio
- -57.45
- Dividend Yield
- 0.00%
- Price Target
- $141.00
- Year High
- $131.49
- Year Low
- $76.53
- Payout Ratio
- $0.00
- Current Ratio
- $7.33
Industry, Sector & symbol
| Stock Exchange | NASDAQ Global Select |
| CEO | Dr. Ugur Sahin M.D. |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | BNTX |
| CUSIP | 09075V102 |
| CIK | 0001776985 |
| Web | https://www.biontech.de |
| Phone | 49 6131 9084 0 |
| Currency | USD |
| Employees | 6133 |
| Country | DE |
Liquidity
| Debt-to-Equity Ratio | 0.01 |
| Payout Ratio | 0.00 |
| Current Ratio | 7.33 |
| Quick Ratio | 7.21 |
| Cash Ratio | 3.82 |
Sales & Book Value
| Annual Sales | $3.82B |
| Price / Sales | 8.82 |
| Cash Flow | 4.11 |
| Price / Cash Flow | 27.23 |
| Price / Book | 1.40 |
Price Target and Rating
| Average Stock Price Forecast | $141.00 |
| High Stock Price Forecast | $359.00 |
| Low Stock Price Forecast | $95.00 |
| Forecast Upside/Downside | -16.04% |
| Consensus Rating | Neutral |
| Rating Score(0-5) | 3 |
| Research Coverage | 18 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $3.83 |
| Trailing P/E Ratio | -57.45 |
| PEG Ratio | -8.62 |
| P/E Growth | -8.62 |
| Net Income | $930.3M |
| Net Margin | -15.36% |
| Pretax Margin | -10.38% |
| Return on Equity | -2.38% |
| Return on Assets | -2.08% |
Financials Score
| AltmanZ Score | 7.26 |
| Piotroski Score | 3.00 |
| Working Capital | 15.96B |
| Total Assets | 22.4B |
| Ebit | -580.3M |
| Market Cap | 28.38B |
| Total Liabilities | 3.29B |
Poll Results
About BioNTech SE (NASDAQ:BNTX) Stock
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase 1a/1b clinical tri ... al to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 to treat solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II clinical trial to treat solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase II clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
BioNTech Stock Has Been Hit Hard Since RFK Jr.'s Nomination. Why This Analyst Upgraded It.
2024-11-19 11:57:00
Evercore ISI analyst Cory Kasimov upgrades the German drugmaker's stock to Outperform from In Line.
Analysts Turn Bullish on BioNTech Stock Amid Volatility
2024-11-19 10:19:27
BioNTech SE ADR (NASDAQ:BNTX) stock is up 2.8% to trade at $825.41 at last glance, after an Evercore ISI upgrade to "outperform" from "in-line.
BioNTech and Moderna at vanguard of new treatment wave - but which is best?
2024-11-19 05:14:00
The mRNA (messenger RNA) technology that powered the rapid development of COVID-19 vaccines is now driving a broader revolution in medicine. According to Berenberg, this innovative approach has the potential to transform the treatment of multiple ailments, particularly cancer and infectious diseases.
Vaccine Maker Stocks Slump After RFK Jr. Nominated as HHS Head
2024-11-15 12:55:46
In the 2024 presidential election's latest impact on the stock markets, shares of several vaccine makers were down Friday morning following the nomination of Robert F. Kennedy Jr. to head the Department of Health and Human Services.
European And US Vaccine Stocks Are Under Pressure - Here's WHy
2024-11-15 11:21:18
Some large European and U.S. vaccine maker stocks have fallen in reaction to Robert F. Kennedy Jr.'s nomination to lead the Department of Health and Human Services.
Frequently Asked Questions
-
What is the current BioNTech SE (BNTX) stock price?
-
BioNTech SE(NASDAQ:BNTX) stock price is $118.39 in the last trading session. During the trading session, BNTX stock reached the peak price of $131.49 while $76.53 was the lowest point it dropped to. The percentage change in BNTX stock occurred in the recent session was --1.93% while the dollar amount for the price change in BNTX stock was -$-2.33.
-
BNTX's industry and sector of operation?
-
The NASDAQ listed BNTX is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of BNTX?
-
Dr. James Timothy Patrick Ryan Ph.D. | Chief Legal & Business Officer & Member of the Management Board
Dr. Ugur Sahin M.D. | Co-Founder, Chief Executive Officer & Chair of the Management Board
Ms. Lisa Birringer | Senior Vice President of Global Financial Reporting & Accounting
Dr. Katalin Kariko Ph.D. | Senior Vice President & External Consultant for RNA Protein Replacement Therapies
Mr. Sean Marett | Executive Officer -
How many employees does BNTX have?
-
Number of BNTX employees currently stands at 6133. BNTX operates from An der Goldgrube 12, Mainz, None 55131, DE.
-
Link for BNTX official website?
-
Official Website of BNTX is: https://www.biontech.de
-
How do I contact BNTX?
-
BNTX could be contacted at phone #49 6131 9084 0 and can also be accessed through its website. BNTX operates from An der Goldgrube 12, Mainz, None 55131, DE.
-
How many shares of BNTX are traded daily?
-
The average number of BNTX shares traded daily for last 3 months was 1.14M.
-
What is the market cap of BNTX currently?
-
The market value of BNTX currently stands at $28.38B with its latest stock price at $118.39